Figure 1From: Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial Study flowchart of Part A (cross-sectional screening). All kidney transplant recipients from our outpatient service with a functioning allograft at 6 months and estimated glomerular filtration rate >20 ml/minute/1.73 m2 will be considered for study inclusion. AMR, antibody-mediated rejection; DSA, donor-specific antibodies.Back to article page